Skip to main content
. 2016 Oct 10;7(5):352–369. doi: 10.5306/wjco.v7.i5.352

Table 2.

Systematic chart of searching methodology and the results based on PubMed

DNA-targeted therapies Agents Akt modulation
All papers1 Non-original2 Relevant papers3 PI3K/Akt inhibitors4
LY294002 Wortmannin BEZ235 Perifosine MK2206
Platinum Carboplatin 68 6 51 3 1 0 0 4
Cisplatin 631 15 589 85 22 8 9 5
Oxaliplatin 71 5 59 5 2 0 0 0
Taxane Docetaxel 149 13 127 9 2 3 1 3
Paclitaxel 363 18 331 47 15 4 2 5
Antimetabolite Fluorouracil 191 5 174 18 6 0 2 3
Gemcitabine 213 14 191 16 8 3 1 1
Pemetrexed 35 3 32 5 2 1 0 0
Radiation Irradiation/radiation 1649 186 1356 151 82 12 13 5
Total articles (9 agents) 3370 265 2910 339 140 31 28 26
1

Terms used in the search: Query agent/radiation, and Akt, within whole the article with no language limitation, as of September, 2014;

2

Including the retracted publication, duplicate publication or non-original papers, including Review articles, Letters and Editorials, Comments, Case Reports, etc.;

3

Relevant with regard to the modulation of Akt by the query agent. [p-Akt OR pAkt OR "phospho-Akt" OR (phosphorylat* Akt) OR “Akt phosphorylation” OR “Akt inhibition” OR “Akt modulation” OR (inhibit* Akt) OR “inactivation of Akt” OR “Akt inactivation” OR “activation of Akt” OR “inactivating Akt”];

4

Suppressing Akt cascade by a PI3K/Akt inhibitor to sensitize the query agent. PI3K: Phosphatidylinositol 3 kinase.